Details for Patent: 10,125,171
✉ Email this page to a colleague
Which drugs does patent 10,125,171 protect, and when does it expire?
Patent 10,125,171 protects SYFOVRE and EMPAVELI and is included in two NDAs.
This patent has thirty patent family members in twelve countries.
Summary for Patent: 10,125,171
| Title: | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
| Abstract: | In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. |
| Inventor(s): | Francois; Cedric (Louisville, KY), Deschatelets; Pascal (Louisville, KY) |
| Assignee: | Apellis Pharmaceuticals, Inc. (Crestwood, KY) |
| Application Number: | 14/116,591 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 10,125,171
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,125,171
| PCT Information | |||
| PCT Filed | May 11, 2012 | PCT Application Number: | PCT/US2012/037648 |
| PCT Publication Date: | November 15, 2012 | PCT Publication Number: | WO2012/155107 |
International Family Members for US Patent 10,125,171
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012253294 | ⤷ Sign Up | |||
| Australia | 2017245334 | ⤷ Sign Up | |||
| Australia | 2019226186 | ⤷ Sign Up | |||
| Brazil | 112013028816 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
